keyword
https://read.qxmd.com/read/38536526/pharmacological-and-immunomodulatory-modes-of-action-of-medically-important-phytochemicals-against-arthritis-a-molecular-insight
#1
REVIEW
Aqsa, Shaukat Ali, Muhammad Summer, Saima Yousaf, Laiba Nazakat, Shehzeen Noor
Arthritis is a common illness that affects joints and it may result in inflammation and pain. Even though arthritis usually affects older people, it can also affect children, adults, and both genders. Numerous arthritic mouse models have been developed but the CIA model of rheumatoid arthritis (RA) has received the most attention. With the use of steroids, DMARDs, and NSAIDs, therapy objectives such as reduced disease incidence and better pain management are achieved. Long-term usage of these therapeutic approaches may have negative side effects...
March 27, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38530664/factors-associated-of-long-term-retention-rate-of-janus-kinase-inhibitors-in-a-multi-failure-rheumatoid-arthritis-population
#2
JOURNAL ARTICLE
Marco Sebastiani, Alen Zabotti, Bruno Biasi, Sofia Cacioppo, Gilda Sandri, Ivan Giovannini, Andreina Manfredi, Luca Quartuccio
OBJECTIVES: We aimed to retrospectively evaluate retention rate and causes of discontinuation of JAKi in RA patients with particular regards to difficult-to-treat subgroups. METHODS: The diffusion of Janus kinase inhibitors (JAKi) for the treatment of rheumatoid arthritis (RA) has rapidly increased in recent years due to their effectiveness, even in difficult-to-treat subgroups of patients. After the publication of the Oral Surveillance study, the labelling of JAKi was modified, advising against their use in elderly patients and those at risk for cardiovascular events and malignancies...
March 26, 2024: Clinical and Experimental Rheumatology
https://read.qxmd.com/read/38529117/retention-rate-of-biologic-and-targeted-synthetic-anti-rheumatic-drugs-in-elderly-rheumatoid-arthritis-patients-data-from-gisea-registry
#3
JOURNAL ARTICLE
Andreina Manfredi, Marco Fornaro, Chiara Bazzani, Simone Perniola, Alberto Cauli, Alessandra Rai, Ennio Giulio Favalli, Serena Bugatti, Maurizio Rossini, Rosario Foti, Fabrizio Conti, Giuseppe Lopalco, Anna Scalvini, Cristina Garufi, Mattia Congia, Roberto Gorla, Elisa Gremese, Fabiola Atzeni, Roberto Caporali, Florenzo Iannone, Marco Sebastiani
OBJECTIVES: An increased number of elderly individuals affected by rheumatoid arthritis (RA) has been reported, including both patients with RA onset in advanced age and patients aged with the disease. In this registry-based study, we aimed to analyze the retention rate and cause of discontinuation of biologic (b) and targeted synthetic (ts)-disease-modifying anti-rheumatic drugs (DMARDs) in RA patients over 65 year old. METHODS: RA patients enrolled in the Italian GISEA registry and starting a b- or a ts-DMARD over 65 years of age were included...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38524267/can-we-achieve-pain-stratification-in-musculoskeletal-conditions-implications-for-clinical-practice
#4
REVIEW
Nidhi Sofat, Andrew Lambarth
In the last few years there has been an increased appreciation that pain perception in rheumatic and musculoskeletal diseases (RMDs) has several mechanisms which include nociceptive, inflammatory, nociplastic and neuropathic components. Studies in specific patient groups have also demonstrated that the pain experienced by people with specific diagnoses can present with distinctive components over time. For example, the pain observed in rheumatoid arthritis has been widely accepted to be caused by the activation of nociceptors, potentiated by the release of inflammatory mediators, including prostaglandins, leukotrienes and cytokine networks in the joint environment...
2024: Front Pain Res (Lausanne)
https://read.qxmd.com/read/38524108/-rheumatoid-arthritis-remission-without-biotherapy-the-experience-of-burkina-faso-west-africa
#5
JOURNAL ARTICLE
Aboubakar Ouédraogo, Fulgence Kabore, Wendlasida Joëlle Stéphanie Zabsonré/Tiendrebéogo, Victor Nonguierma, Binta Savadogo, Kantiga Aida Eudoxie Abassiri, Yamyellé Enselme Zongo, Richard Damade, Dieu-Donné Ouédraogo
INTRODUCTION: the objective of this study was to evaluate the therapeutic response of patients treated with disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis (RA). METHODS: descriptive and analytical single-center cross-sectional study conducted in Burkina Faso from January 2019 to December 2021 in patients with RA meeting American Rheumatism Association/European League against rheumatism criteria. Therapeutic response was assessed according to the criteria of the European League Against Rheumatism, the clinical disease activity index and the simplified disease activity Index after at least six months of treatment...
2024: Pan African Medical Journal
https://read.qxmd.com/read/38519107/medication-utilisation-trends-during-pregnancy-and-factors-influencing-adverse-pregnancy-outcomes-in-patients-with-rheumatoid-arthritis
#6
JOURNAL ARTICLE
Yeo-Jin Song, Soo-Kyung Cho, Yu-Seon Jung, Sun-Young Jung, Jihyun Keum, Eunwoo Nam, Yoon-Kyoung Sung, Dae Hyun Yoo
OBJECTIVES: We aimed to investigate medication utilisation trends during pregnancy and identify factors associated with adverse pregnancy outcomes (APOs) in patients with rheumatoid arthritis (RA). METHODS: Female patients with RA aged 20-50 years were identified from the Korean national health insurance database between 2010 and 2020. Pregnancy episodes were divided into two groups according to pregnancy outcome: the delivery group and the APO group (abortion and stillbirth)...
March 22, 2024: RMD Open
https://read.qxmd.com/read/38515982/advantages-of-chinese-herbal-medicine-in-treating-rheumatoid-arthritis-a-focus-on-its-anti-inflammatory-and-anti-oxidative-effects
#7
REVIEW
Xiaoyu Wang, Youqian Kong, Zeguang Li
Oxidative stress is a condition characterized by an imbalance between the oxidative and antioxidant processes within the human body. Rheumatoid arthritis (RA) is significantly influenced by the presence of oxidative stress, which acts as a pivotal factor in its pathogenesis. Elevated levels of mitochondrial reactive oxygen species (ROS) and inflammation have been found to be closely associated in the plasma of patients with RA. The clinical treatment strategies for this disease are mainly chemical drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), glucocorticoids (GCs) and biological agents, but it is difficult for patients to accept long-term drug treatment and its side effects...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38512921/biomarker-combination-predicting-imminent-relapse-after-discontinuation-of-biological-drugs-in-patients-with-rheumatoid-arthritis-in-remission
#8
JOURNAL ARTICLE
Eiji Sakashita, Katsuya Nagatani, Hitoshi Endo, Seiji Minota
OBJECTIVES: Compared to conventional disease-modifying antirheumatic drugs (DMARDs), biological DMARDs demonstrate superior efficacy but come with higher costs and increased infection risks. The ability to stop and resume biological DMARD treatment while maintaining remission would significantly alleviate these barriers and anxieties. The objective of this study was to identify biomarkers that can predict an imminent relapse, hopefully enabling the timely resumption of biological DMARDs before relapse occurs...
2024: PloS One
https://read.qxmd.com/read/38512065/combination-biologics-or-targeted-synthetic-disease-modifying-anti-rheumatic-drugs-in-the-treatment-of-spondyloarthritis-a-systematic-literature-review
#9
REVIEW
Rand Abedalweli, Michelle Nguyen, Atul Deodhar
INTRODUCTION: The advent of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have transformed the management of immune-mediated rheumatic diseases, including spondylarthritis (SpA). However, the data about combining b/ts DMARDs in the treatment of SpA are scarce. The study objectives were to assess the efficacy and safety of combination b/tsDMARD in SpA. METHODS: We conducted systematic literature review (PubMed and Medline) with two independent reviewers, one adjudicator, exploring the efficacy and safety of combination b/tsDMARDs in the treatment of SpA...
March 21, 2024: Expert Review of Clinical Immunology
https://read.qxmd.com/read/38509351/the-interplay-between-rheumatic-diseases-and-pulmonary-health
#10
REVIEW
Yuliya Fedorchenko, Olena Zimba, Roman Yatsyshyn, Bohdana Doskaliuk, Liubomyr Zaiats, Mykhailo Fedorchenko
Patients with rheumatic diseases (RDs) are prone to a number of comorbidities, particularly those affecting the respiratory system due to inflammatory and autoimmune mechanisms. Rheumatoid arthritis (RA), systemic sclerosis (SSc), and inflammatory idiopathic myopathies (IIMs) often present with progressive interstitial lung disease (ILD). The prevalence of ILD varies among patients with RDs, with 11% in RA, 47% in SSc, and 41% in IIMs. Some diagnostic markers, including KL-6, cytokines TNF-α and IL-6, and autoantibodies (anti-CCP), play a crucial role in assessing and predicting the course of pulmonary involvement in RDs...
March 20, 2024: Rheumatology International
https://read.qxmd.com/read/38507187/characteristics-and-6-month-outcomes-in-patients-with-rheumatoid-arthritis-initiating-infliximab-biosimilar-ifx-dyyb-in-a-real-world-setting
#11
JOURNAL ARTICLE
Joshua F Baker, Catherine Bakewell, Ara Dikranian, Gordon Lam, Jacqueline O'Brien, Page C Moore, Miao Yu, Peter Hur, Karim R Masri
INTRODUCTION: Real-world studies describing biosimilar initiation or switching in patients with rheumatoid arthritis (RA) are limited. The aim of this study was to assess treatment patterns and effectiveness of real-world patients with RA initiating infliximab biosimilar IFX-dyyb (CT-P13; Inflectra® ) in the USA. METHODS: This observational study evaluated patients with RA from the CorEvitas RA Registry who initiated IFX-dyyb and had Clinical Disease Activity Index (CDAI) recorded at baseline and 6 months...
March 20, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38503473/efficacy-and-safety-of-pharmacological-treatment-of-psoriatic-arthritis-a-systematic-literature-research-informing-the-2023-update-of-the-eular-recommendations-for-the-management-of-psoriatic-arthritis
#12
JOURNAL ARTICLE
Andreas Kerschbaumer, Josef S Smolen, Ricardo J O Ferreira, Heidi Bertheussen, Xenofon Baraliakos, Daniel Aletaha, Dennis G McGonagle, Désirée van der Heijde, Iain B McInnes, Bente Appel Esbensen, Kevin L Winthrop, Wolf-Henning Boehncke, Jan W Schoones, Laure Gossec
OBJECTIVES: To obtain an overview of recent evidence on efficacy and safety of pharmacological treatments in psoriatic arthritis (PsA). METHODS: This systematic literature research (SLR) investigated the efficacy and safety of conventional synthetic (cs), biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) in patients with PsA. A systematic database search using Medline, EMBASE, Cochrane CENTRAL was conducted to identify relevant articles published since the previous update in 2019 until 28 December 2022...
March 19, 2024: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/38498139/efficacy-and-safety-of-risankizumab-for-active-psoriatic-arthritis-100-week-results-from-the-keepsake%C3%A2-2-randomized-clinical-trial
#13
JOURNAL ARTICLE
Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan Kivitz
INTRODUCTION: Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had inadequate response/intolerance to ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and/or 1-2 biologic DMARDs (bDMARD-IR). Herein, we report results through 100 weeks of treatment. METHODS: KEEPsAKE 2 is a global phase 3 trial...
March 18, 2024: Rheumatology and Therapy
https://read.qxmd.com/read/38494304/the-impact-of-covid-19-and-other-factors-on-the-usage-status-of-the-biologic-drug-therapies-for-rheumatoid-arthritis-a-study-from-vietnam
#14
JOURNAL ARTICLE
Hai-Binh Bui, Hong-Thinh Lai, Thanh-Lam Nguyen, Thuy-Duong Vu, Nhat-Le Bui, Van-Hung Nguyen, Thi-To-Chau Tran, Thi-Phuong-Thuy Nguyen, Thi-Ngoc-Lan Nguyen, Jaffar A Al-Tawfiq, Dinh-Toi Chu
OBJECTIVES: To describe the status of using biological Disease Modifying Anti Rheumatic Drugs (bDMARDs) to treat rheumatoid arthritis (RA) and related factors. In addition, the study determined the impact of COVID-19 on the usage of bDMARDs. METHODS: This is a cross-sectional study and included 219 RA patients over 18 years old. The Kaplan-Meier method and the log-rank test (p<0.05) were used to estimate the retention time and compare between different times...
March 2024: Reumatología clinica
https://read.qxmd.com/read/38489323/potential-efficacy-of-t-and-b-lymphocyte-targeted-therapies-on-articular-involvement-of-patients-with-rheumatoid-arthritis-and-systemic-sclerosis-overlap-syndrome-results-from-a-2-centre-series-of-22-cases
#15
JOURNAL ARTICLE
Nans Lebel, Isabelle Marie, Julien Grosjean, Pauline Brevet, Mathilde Leclercq, Anaël Dumont, Hervé Levesque, Ygal Benhamou, Christian Marcelli, Thierry Lequerre, Olivier Vittecoq
OBJECTIVES: To analyse in routine practice the efficacy of targeted therapies on joint involvement of patients with rheumatoid arthritis/systemic sclerosis (RA/SSc) overlap syndrome. METHODS: This was a retrospective analysis of medical records of two academic centres over a 10-year period. Joint response to targeted therapies was measured according to EULAR criteria based on Disease Activity Score (DAS)-28. In addition, changes in CRP level and glucocorticoid consumption were recorded...
March 13, 2024: Clinical and Experimental Rheumatology
https://read.qxmd.com/read/38479734/comparative-effectiveness-of-baricitinib-and-alternative-biological-dmards-in-a-swiss-cohort-study-of-patients-with-ra
#16
JOURNAL ARTICLE
Benoit Thomas P Gilbert, Denis Mongin, Romain Aymon, Kim Lauper, Cédric Laedermann, Clémentine Perrier, Ruediger Mueller, Delphine S Courvoisier, Axel Finckh
OBJECTIVES: This observational study compares the effectiveness of baricitinib (BARI), a targeted synthetic disease-modifying antirheumatic drug (tsDMARD), with alternative biological DMARDs (bDMARDs) in patients with rheumatoid arthritis (RA), from a prospective, longitudinal cohort. METHODS: We compared patients initiating a treatment course (TC) of BARI, tumour necrosis factor inhibitors (TNFi) or bDMARDs with other modes of action (OMA), during a period when all these DMARDs were available in Switzerland...
March 12, 2024: BMJ Open
https://read.qxmd.com/read/38479179/personalized-cardiovascular-risk-assessment-in-rheumatoid-arthritis-patients-using-circulating-molecular-profiles-and-their-modulation-by-tnfi-il6ri-and-jakinibs
#17
JOURNAL ARTICLE
Laura Muñoz-Barrera, Carlos Perez-Sanchez, Rafaela Ortega-Castro, Sagrario Corrales, Maria Luque-Tevar, Tomás Cerdó, Ismael Sanchez-Pareja, Pilar Font, Raquel Lopez-Mejías, Jerusalem Calvo, M Carmen Abalos-Aguilera, Desiree Ruiz-Vilchez, Pedro Segui, Christian Merlo, José Perez-Venegas, Ma Dolores Ruiz Montesino, Carlos Rodriguez-Escalera, Carmen Romero Barco, Antonio Fernandez-Nebro, Natalia Mena Vazque, Jose Luis Marenco, Julia Uceda Montañes, Javier Godoy-Navarrete, Alba Ma Cabezas-Lucena, Eduardo Collantes Estevez, Ma Angeles Aguirre, Miguel A González-Gay, Nuria Barbarroja, Alejandro Escudero-Contreras, Chary Lopez-Pedrera
BACKGROUND & OBJECTIVES: This study aimed to: 1) analyze the inflammatory profile of Rheumatoid Arthritis (RA) patients, identifying clinical phenotypes associated with cardiovascular (CV) risk; 2) evaluate biologic and targeted-synthetic disease-modifying antirheumatic drugs (b-DMARDs and ts-DMARDs': TNFi, IL6Ri, JAKinibs) effects; and 3) characterize molecular mechanisms in immune-cell activation and endothelial dysfunction. PATIENTS & METHODS: A total of 387 RA patients and 45 healthy donors were recruited, forming three cohorts: i) 208 RA patients with established disease but without previous CV events; ii) RA-CVD: 96 RA patients with CV events, and iii) 83 RA patients treated with b-DMARDs/ts-DMARDs for 6 months...
March 12, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38477771/bub1-suppresses-inflammatory-arthritis-associated-bone-loss-in-mice-through-inhibition-of-tnf%C3%AE-mediated-osteoclastogenesis
#18
JOURNAL ARTICLE
Shuhei Yoshida, Aoi Ikedo, Yuta Yanagihara, Tomohisa Sakaue, Noritaka Saeki, Yuuki Imai
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by synovitis, bone and cartilage destruction, and increased fracture risk with bone loss. Although disease-modifying anti-rheumatic drugs (DMARDs) have dramatically improved clinical outcomes, these therapies are not universally effective in all patients due to the heterogeneity of RA pathogenesis. Therefore, it is necessary to elucidate the molecular mechanisms underlying RA pathogenesis, including associated bone loss, in order to identify novel therapeutic targets...
January 27, 2024: Journal of Bone and Mineral Research
https://read.qxmd.com/read/38477623/role-of-platelet-lymphocyte-neutrophil-lymphocyte-and-interleukin-37-interleukin-17-ratios-in-the-occurrence-and-treatment-of-rheumatoid-arthritis
#19
JOURNAL ARTICLE
Yan Meng, Xuan-Lin Cai, Shan Cong, Jiao Sun, Yong-Wei Hu, Yan-Qin Gu, Xiu-Min Ma, Li Luo
This study was designed to investigate the correlation of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and interleukin (IL)-37/IL-17 ratio with the incidence/treatment of rheumatoid arthritis (RA). Firstly, fifty-eight patients with RA treated at the first affiliated hospital of Xinjiang Medical University from January 2018 to January 2019 were selected as the RA group; forty-nine healthy volunteers were enrolled in the control group. RA patients were treated with disease-modifying anti-rheumatic drugs (DMARDs)...
March 13, 2024: Immunological Investigations
https://read.qxmd.com/read/38473928/potential-rheumatoid-arthritis-associated-interstitial-lung-disease-treatment-and-computational-approach-for-future-drug-development
#20
REVIEW
Eunji Jeong, Hyunseok Hong, Yeon-Ah Lee, Kyoung-Soo Kim
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by swelling in at least one joint. Owing to an overactive immune response, extra-articular manifestations are observed in certain cases, with interstitial lung disease (ILD) being the most common. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is characterized by chronic inflammation of the interstitial space, which causes fibrosis and the scarring of lung tissue. Controlling inflammation and pulmonary fibrosis in RA-ILD is important because they are associated with high morbidity and mortality...
February 26, 2024: International Journal of Molecular Sciences
keyword
keyword
86203
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.